The efficacy of sertraline in panic disorder

Combined results from two fixed-dose studies

Javaid Sheikh, P. Londborg, C. M. Clary, R. Fayyad

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Data from two fixed-dose studies of sertraline in panic disorder were pooled in order to provide sufficient power for the analysis of treatment response in clinically relevant subgroups. Male and non-fertile female patients meeting DSM-III-R criteria for moderate-to-severe panic disorder with or without agoraphobia completed a 1-2 week placebo run-in period, and then were randomized to 12 weeks of double-blind treatment with either placebo, or one of three fixed daily doses of sertraline (50 mg, 100 mg, or 200 mg). Eighty-two patients were treated with placebo and 240 patients were treated with one of three doses of sertraline. All three sertraline doses produced significant efficacy compared to placebo, with no consistent evidence of a dose-response effect. For the subset of patients with subsyndromic depression at baseline [baseline Hamilton Depression Rating scale (HAM-D > 12 and ≤21], sertraline yielded a significantly higher panic-free rate than did placebo (P = 0.021), again, by a conservative endpoint (Last Observation Carried Forward method, LOCF) analysis. Sertraline was well-tolerated at all dose levels, with no significant between-dose differences in patients discontinuing due to adverse events. The presence of mild-to-moderate subsyndromic levels of depression did not reduce the anti-panic efficacy of sertraline. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish
Pages (from-to)335-342
Number of pages8
JournalInternational Clinical Psychopharmacology
Volume15
Issue number6
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Sertraline
Panic Disorder
Placebos
Panic
Depression
Agoraphobia
Diagnostic and Statistical Manual of Mental Disorders
Observation
Therapeutics

Keywords

  • Affective symptoms
  • Antidepressive agents
  • Depression
  • Dose-response relationship
  • Drug
  • Panic disorder
  • Phobic disorders
  • Sertraline

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The efficacy of sertraline in panic disorder : Combined results from two fixed-dose studies. / Sheikh, Javaid; Londborg, P.; Clary, C. M.; Fayyad, R.

In: International Clinical Psychopharmacology, Vol. 15, No. 6, 2000, p. 335-342.

Research output: Contribution to journalArticle

@article{bd8a81b8e15244f88b4b5028542f1838,
title = "The efficacy of sertraline in panic disorder: Combined results from two fixed-dose studies",
abstract = "Data from two fixed-dose studies of sertraline in panic disorder were pooled in order to provide sufficient power for the analysis of treatment response in clinically relevant subgroups. Male and non-fertile female patients meeting DSM-III-R criteria for moderate-to-severe panic disorder with or without agoraphobia completed a 1-2 week placebo run-in period, and then were randomized to 12 weeks of double-blind treatment with either placebo, or one of three fixed daily doses of sertraline (50 mg, 100 mg, or 200 mg). Eighty-two patients were treated with placebo and 240 patients were treated with one of three doses of sertraline. All three sertraline doses produced significant efficacy compared to placebo, with no consistent evidence of a dose-response effect. For the subset of patients with subsyndromic depression at baseline [baseline Hamilton Depression Rating scale (HAM-D > 12 and ≤21], sertraline yielded a significantly higher panic-free rate than did placebo (P = 0.021), again, by a conservative endpoint (Last Observation Carried Forward method, LOCF) analysis. Sertraline was well-tolerated at all dose levels, with no significant between-dose differences in patients discontinuing due to adverse events. The presence of mild-to-moderate subsyndromic levels of depression did not reduce the anti-panic efficacy of sertraline. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Affective symptoms, Antidepressive agents, Depression, Dose-response relationship, Drug, Panic disorder, Phobic disorders, Sertraline",
author = "Javaid Sheikh and P. Londborg and Clary, {C. M.} and R. Fayyad",
year = "2000",
language = "English",
volume = "15",
pages = "335--342",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The efficacy of sertraline in panic disorder

T2 - Combined results from two fixed-dose studies

AU - Sheikh, Javaid

AU - Londborg, P.

AU - Clary, C. M.

AU - Fayyad, R.

PY - 2000

Y1 - 2000

N2 - Data from two fixed-dose studies of sertraline in panic disorder were pooled in order to provide sufficient power for the analysis of treatment response in clinically relevant subgroups. Male and non-fertile female patients meeting DSM-III-R criteria for moderate-to-severe panic disorder with or without agoraphobia completed a 1-2 week placebo run-in period, and then were randomized to 12 weeks of double-blind treatment with either placebo, or one of three fixed daily doses of sertraline (50 mg, 100 mg, or 200 mg). Eighty-two patients were treated with placebo and 240 patients were treated with one of three doses of sertraline. All three sertraline doses produced significant efficacy compared to placebo, with no consistent evidence of a dose-response effect. For the subset of patients with subsyndromic depression at baseline [baseline Hamilton Depression Rating scale (HAM-D > 12 and ≤21], sertraline yielded a significantly higher panic-free rate than did placebo (P = 0.021), again, by a conservative endpoint (Last Observation Carried Forward method, LOCF) analysis. Sertraline was well-tolerated at all dose levels, with no significant between-dose differences in patients discontinuing due to adverse events. The presence of mild-to-moderate subsyndromic levels of depression did not reduce the anti-panic efficacy of sertraline. (C) 2000 Lippincott Williams and Wilkins.

AB - Data from two fixed-dose studies of sertraline in panic disorder were pooled in order to provide sufficient power for the analysis of treatment response in clinically relevant subgroups. Male and non-fertile female patients meeting DSM-III-R criteria for moderate-to-severe panic disorder with or without agoraphobia completed a 1-2 week placebo run-in period, and then were randomized to 12 weeks of double-blind treatment with either placebo, or one of three fixed daily doses of sertraline (50 mg, 100 mg, or 200 mg). Eighty-two patients were treated with placebo and 240 patients were treated with one of three doses of sertraline. All three sertraline doses produced significant efficacy compared to placebo, with no consistent evidence of a dose-response effect. For the subset of patients with subsyndromic depression at baseline [baseline Hamilton Depression Rating scale (HAM-D > 12 and ≤21], sertraline yielded a significantly higher panic-free rate than did placebo (P = 0.021), again, by a conservative endpoint (Last Observation Carried Forward method, LOCF) analysis. Sertraline was well-tolerated at all dose levels, with no significant between-dose differences in patients discontinuing due to adverse events. The presence of mild-to-moderate subsyndromic levels of depression did not reduce the anti-panic efficacy of sertraline. (C) 2000 Lippincott Williams and Wilkins.

KW - Affective symptoms

KW - Antidepressive agents

KW - Depression

KW - Dose-response relationship

KW - Drug

KW - Panic disorder

KW - Phobic disorders

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=0033760579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033760579&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 335

EP - 342

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 6

ER -